---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-000035"
form_type: "8-K"
ticker: "DXR"
cik: "0000027367"
company_name: "DAXOR CORP"
filed_at: "2024-01-02T23:59:59+00:00"
generated_at: "2026-06-07T05:37:19.273601+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Daxor submits next-gen BVA to FDA for 510(k)/CLIA-waiver; clearance expected H1 2024

## Summary
- Submission via dual 510(k)/CLIA-waiver pathway to FDA for next-generation blood volume analyzer.
- New device designed to be three times faster, simpler, portable, and capable of bedside analysis.
- Development funded under contract by U.S. Department of Defense.
- Potential FDA clearance is expected during the first half of 2024.
- Current BVA-100 is only FDA-cleared diagnostic for direct blood volume measurement.

## SEC filing metadata
- accession: 0001493152-24-000035
- form_type: 8-K
- ticker: DXR
- cik: 0000027367
- company_name: DAXOR CORP
- filed_at: 2024-01-02T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/27367/000149315224000035/0001493152-24-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/27367/000149315224000035/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-000035
- JSON: https://secwatch.observer/filing/0001493152-24-000035.json
- Plain text: https://secwatch.observer/filing/0001493152-24-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.